Study: Early Identification Needed for Mesothelioma Advances

Professor John Cherrie at Heriot-Watt University in the United Kingdom believes future treatment advances and improved patient outcomes for mesothelioma rests with a formula to better identify and screen high-risk patients. It could make an early diagnosis of the asbestos-related cancer much more common. Cherrie said the current standard — which typically results in a late-stage diagnosis and a poor prognosis — prevents novel treatment studies and the development of any pre-emergent strategy to combat the aggressive cancer. “We don’t pretend to have a medical cure that will help immediately, but until we can start identifying patients earlier, we can’t even try out what might work,” Cherrie, an occupational medicine specialist in the School of Engineering and Physical Sciences at Heriot-Watt, told Asbestos.com. “The patients are usually too sick. It’s tough to make progress that way.” Cherrie is the lead author in a study published recently in the International Journal of Hygiene and Environmental Health, detailing the asbestos-exposure formula he believes would work. “Right now, we don’t have a way of identifying early-stage disease,” he said. “Usually by the time it is diagnosed, it’s virtually untreatable. We want to find a way to change that.” Pre-Emergent Treatment Strategies Mesothelioma is caused almost exclusively by exposure to toxic asbestos, typically in long-term occupationa...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Activity emission potential biomarkers for mesothelioma chemoprophylaxis strategies early diagnosis mesothelioma Early identification of mesothelioma early screening asbestos Heriot-Watt University high-risk mesothelioma indwelling pleural Source Type: news

Related Links:

Cancer patients — including those with mesothelioma — who receive complementary therapy are likely to die sooner than those who use only conventional treatment, according to researchers at Yale School of Medicine. Patients receiving complementary medicine also were more inclined to forego at least one component of their conventional treatment regimen. The study was done by a team from the Yale Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine. JAMA Oncology published the study July 19. “The study was about patients who were using unproven therapies for treatment...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsThis survey is the first LA effort to publish current practice indications and treatment protocols of PD. Achieving consensus of best therapeutic options is essential to provide the best possible outcomes for patients with PD who could benefit from CRS with HIPEC therefore aiming at standardization of the procedure.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
ConclusionThe combined treatment for peritoneal carcinomatosis may be performed safely with acceptable morbidity and mortality in a specialized unit setting. Although over half of patients underwent normothermic intraperitoneal chemotherapy, our results were comparable to results from others centers.ResumoIntroduçãoO objetivo foi avaliar o tratamento combinado da cirurgia citorredutora e quimioterapia intraperitoneal em pacientes com carcinomatose peritoneal secundária ao câncer colorretal, pseudomixoma peritoneal e mesotelioma.MétodosForam obtidos dados de 73 pacientes com carcinomatose p...
Source: Journal of Coloproctology - Category: Gastroenterology Source Type: research
More than 40 patients with mesothelioma have been screened for NCI-MATCH, the novel clinical trial pairing tumor-related gene abnormalities with a drug targeting the corresponding mutation, regardless of cancer type. The multicenter program is the largest precision medicine clinical trial ever conducted, with more than 5,500 patients already participating nationwide. The National Cancer Institute (NCI) sponsors the phase II trial called Molecular Analysis for Therapy Choice (MATCH), which opened in 2015. The study was designed for patients with various solid tumors, myeloma and lymphoma that have progressed after standard-...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The recent suicides of highly regarded fashion designer Kate Spade and television celebrity chef and author Anthony Bourdain remind us this mental health crisis can touch anyone. Cancer patients are no exception. According to the Centers for Disease Control and Prevention (CDC), suicide rates between 1999 and 2016 have risen more than 30 percent in half of the country and by nearly 60 percent in some states. This trend is particularly worrisome for cancer patients because this group has a higher suicide risk than the general public. For mesothelioma patients and the people who care for them, one part of this picture deser...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Authors: Bochtler T, Endris V, Reiling A, Leichsenring J, Schweiger MR, Klein S, Stögbauer F, Goeppert B, Schirmacher P, Krämer A, Stenzinger A Abstract This case report presents a male patient with epithelioid mesothelioma that was initially misdiagnosed as cancer of unknown primary (CUP) and correctly identified using molecular panel sequencing. The patient had a prior history of colon and breast cancer. To assess the enlarged mediastinal lymph nodes, retrosternal lymphadenectomy was performed in 2016. The lymph nodes were histologically deemed unrelated to the known breast cancer by the reference patho...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
Abstract BACKGROUND: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are used in the management of selected peritoneal malignancies. While most patients achieve long-term disease-free survival, there remains a group with early recurrence (ER). We aim to investigate the clinical factors associated with ER. METHODS: A retrospective review of a prospectively maintained database of CRS-HIPEC patients treated between April 2001 and Feb 2016 was performed. ER was defined as recurrence within 12 months of CRS-HIPEC. Patients were stratified according to time to recurrence and only p...
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Tags: Int J Clin Oncol Source Type: research
Oncologist Dr. Arek Dudek at Regions Hospital Cancer Care Center in St. Paul, Minnesota, believes his clinical trial involving a novel immunotherapy combination could change the way doctors treat pleural mesothelioma. Dudek is opening the only Phase II trial evaluating the combination of nivalumab (Opdivo) and ramucirumab (Cyramza) for previously treated mesothelioma patients. “This strategy – if successful, like we think it will be – could make treatment with chemotherapy obsolete,” Dudek told Asbestos.com. “People can be really excited about this one.” He based his optimism on the pote...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSIONS: The risks of perioperative morbidity and mortality after CRS and HIPEC are analogous to any other major gastrointestinal surgery. CRS and HIPEC should remain a treatment option for highly selected patients in whom a curative or life prolonging treatment is a pursuit and should be performed in high volume specialized institutions. PMID: 29589675 [PubMed - as supplied by publisher]
Source: Minerva Chirurgica - Category: Surgery Tags: Minerva Chir Source Type: research
The U.S. Food and Drug Administration (FDA) is investigating the potential for three immunotherapy drugs to cause retinal detachment and vision loss. The FDA will consider adding eye toxicities to the warning labels for pembrolizumab (Keytruda), nivolumab (Opdivo) and ipilimumab (Yervoy), which have shown promise in clinical trials involving malignant mesothelioma. All three have already been approved by the FDA for use with metastatic melanoma. Keytruda and Opdivo also have approval for head and neck cancers, colorectal cancers and certain non-small cell lung cancers. The FDA used its Adverse Event Reporting System (FAERS...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | CT Scan | Environmental Health | Epidemiology | Immunotherapy | Mesothelioma | Occupational Health | Respiratory Medicine | Study | Toxicology | UK Health | X-Ray